reason report
recap lower outlook continu drive market
bottom line remain market perform view
compani still inadequ posit growth biolog
like lose share emerg standard biomolecular
analysi close tie competitor product
adopt new product includ bioaccord cyclic im
remain much longer term view share trade lower
anoth weak quarter driven late-quart weak us led
us pharma declin instrument system sale europ remain
weak first month cc america
flat small molecul continu slow impact
china on-going rule expans fundament believ
continu lag behind peer market trend like
bound acceler see op op continu
gain market share vs mp remain market perform pt
reflect discount higher peer group multipl
instrument sale indic longer term outlook
believ instrument sale indic long-term growth
deliv declin quarter combin lc lc-m
instrument spend quarter believ larg
due instrument inadequ posit growth
biolog like lose share competitor includ
weak instrument sale like yield weak recur
revenu column servic contract long-term
continu priorit share repurchas aggress
invest growth attract acquisit spent
share repurchas quarter expect repurchas anoth
share vs pursu aggress invest growth
alloc capit toward attract acquisit could help expand
adjac market continu expect repurchas
share object increas leverag net-debt/
continu believ new product introduct like
year away needl move new product
introduct includ bioaccord cyclic im introduc asm
earlier like take number year gain adopt
biomolecular qa/qc lab continu benefit q-tof
synapt instrument given market growth biomolecul
also posit bioaccord development stage
biomolecul system ideal regul qa/qc market
howev qa/qc lab director gener amen chang
thu view bioaccord like take year gain meaning
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep present ex-amort one-tim charg
pleas refer page import disclosur price chart analyst certif
traction spec bla nda feedback cyclic im
instrument remain mix medacorp specialist unclear
applic instrument research need
lower guid reflect uncertainti ahead lower
full year organ growth guid given uncertain
market condit mix end market condit europ china
view new product introduct gain traction
market lower revenu estim
prior ep move prior
reflect updat guidanc
rate water share market perform price target view
market perform given earlier sale forc realign continu impact lc-m
sale year believ steadi rise complex biomolecul bring
emerg standard includ mam multi attribut monitor alreadi becom
standard close attach orbitrap platform vs mass spec
pose threat uptak instrument longer term attempt address via
launch bioaccord system product still remain earli take multipl year
gain traction highli regul pharma qa/qc emerg standard rapidli gain
traction drug development head toward stronghold qa/qc despit
lc compani core custom expect mass spec util
ramp higher regul qa/qc industry-lead empow cd softwar
also like see increas competit see empow cd chrom data system
key recur instrument consum sale biopharma qa/qc
like face increas competit chromeleon agil open lab
come time key oper technic leadership transit mani
take retir believ face number headwind multipl front near
term longer term valuat reflect competit headwind compani
increasingli face view share buy-back market cap
strong continu provid support stock near-to-medium term
pt reflect ev/ebitda multipl discount
ev/ebitda lst multipl believ busi under-perform
peer group share current trade consensu ebitda slightli
tool averag believ would warrant higher multipl sale rep reach full
product help drive lc-m growth biopharma market still believ offer
premium product potenti return growth sale rep new mass spec
product challeng launch bioaccord address meet biotherapeut need
market deriv price target appli discount averag ev/ebitda
multipl compris life scienc peer group
primari risk price target includ
could acceler stock repurchas help drive stock higher one could also
envis biopharma uptick drive equival revenu growth across competitor
uptick biopharmaceut fund could pose risk know market remain
fda approv process directli impact biopharma biotech compani
could continu favor older method continu domin biopharma drug
sale could continu acceler result acceler spend current
level revenu deriv biopharma uptick spend
biopharma like increas revenu
acceler global budget research could caus upsid risk forecast expand
budget govern academ fund could result higher revenu rel
estim signific academ exposur revenu ww
nih exposur less revenu pickup academ spend could
headwind rate estim increas global budget could result shift
focu strategi growth could increas oper risk
emerg market pose signific upsid risk view despit signific growth
china far acceler uptak product could impact view sudden
macroeconom chang lead increas fund fund could impact water
posit china repres compani revenu chang regul
lead easier oper china foreign compani like benefit well given
posit market
high attach rate integr part busi model despit entri high
resolut mass spec lc could continu remain demand drive sale higher
estim could continu maintain legaci high attach rate lc
system due requir technolog competit chang market
fda regul remain paramount affect adopt rate clinic diagnost
tool clinic diagnost remain major growth area futur chang
regul restrict use mass spectromet clinic diagnost laboratori could
also improv compani prospect restrict could affect growth adopt rate certain
tool regul would also increas cost complianc test purpos
fx
buy-back
rest
good sold
interest expens incom
sg sale
 sale
oper expens sale
compani report svb leerink estim
